Logo

ACET

Adicet Bio, Inc.

ACET

Adicet Bio, Inc. • NASDAQ
$0.65 ▲ 7.85% (+0.05)
Market Cap $53.98 M
52w High $1.19
52w Low $0.45
Dividend Yield 0%
P/E -0.52
Volume 1.32M
Outstanding Shares 83.28M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $27.952M ▼ $-26.856M ▲ 0% $-0.29 ▲ $-25.271M ▲
Q2-2025 $0 $32.392M ▲ $-31.217M ▼ 0% $-0.34 ▼ $-29.562M ▼
Q1-2025 $0 $29.885M ▼ $-28.214M ▲ 0% $-0.31 ▲ $-26.534M ▲
Q4-2024 $0 $30.743M ▼ $-28.727M ▲ 0% $-0.32 ▲ $-27.103M ▲
Q3-2024 $0 $33.153M $-30.478M 0% $-0.34 $-28.885M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $103.098M ▼ $140.479M ▼ $31.337M ▲ $109.142M ▼
Q2-2025 $124.963M ▼ $162.972M ▼ $29.6M ▼ $133.372M ▼
Q1-2025 $150.439M ▼ $191.271M ▼ $29.825M ▼ $161.446M ▼
Q4-2024 $176.303M ▼ $220.219M ▼ $33.61M ▼ $186.609M ▼
Q3-2024 $202.065M $245.962M $34.431M $211.531M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-26.856M ▲ $-22.307M ▲ $16.836M ▼ $-150K ▼ $-5.621M ▼ $-22.516M ▲
Q2-2025 $-31.217M ▼ $-26.633M ▼ $32.953M ▲ $267K ▲ $6.587M ▲ $-26.68M ▲
Q1-2025 $-28.214M ▲ $-25.397M ▼ $-2.861M ▲ $-104K ▼ $-28.362M ▲ $-26.889M ▼
Q4-2024 $-28.727M ▲ $-24.101M ▼ $-22.12M ▲ $137K ▲ $-46.084M ▲ $-24.277M ▼
Q3-2024 $-30.478M $-22.006M $-96.581M $-96.18K $-118.587M $-22.407M

Revenue by Products

Product Q1-2018Q2-2018Q3-2018Q4-2018
Human Health
Human Health
 $90.00M ▲$370.00M ▲$80.00M ▼$80.00M ▲
Performance Chemicals
Performance Chemicals
 $50.00M ▲$180.00M ▲$40.00M ▼$40.00M ▲
Pharmaceutical Ingredients
Pharmaceutical Ingredients
 $40.00M ▲$160.00M ▲$40.00M ▼$40.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Adicet Bio is still a classic early-stage biotech story: almost no product revenue yet and a steady pattern of operating losses. Research and development and other operating costs clearly outweigh any income, so the company has been running at a loss every year in the period shown. Losses deepened as the pipeline ramped up, then appear to have stabilized more recently, but they remain substantial. This is typical for a clinical‑stage biotech that is investing heavily ahead of any commercial launch and means the business currently depends on external funding rather than internally generated profits.

Balance Sheet

Balance Sheet The balance sheet shows a company with a reasonable asset base for its size but no excess cushion. Cash was previously the dominant asset and has come down meaningfully in the most recent year, although overall assets and equity remain positive. Debt exists but is relatively small compared with total assets and equity, so leverage does not look like the primary risk. The bigger consideration is that equity has been trending down from earlier peaks, signaling that ongoing losses are slowly eating into the capital base unless offset by new financing rounds.

Cash Flow

Cash Flow Cash flow reflects the same early‑stage profile: regular cash outflows from operations with no offsetting inflows from product sales. Operating cash burn has been fairly consistent from year to year, with free cash flow also negative, meaning the company is spending more cash than it generates. Capital spending is modest, so most of the cash use appears to be research, development, and overhead. This pattern is sustainable only as long as the company can continue to access capital markets or partnerships to refill its cash balance.

Competitive Edge

Competitive Edge Adicet Bio sits in a crowded and fast‑moving cell therapy field but is working in a more specialized niche: off‑the‑shelf gamma delta T‑cell therapies. This focus provides differentiation versus many competitors that use more traditional T‑cell approaches. The company’s competitive position rests on three main pillars: a specialized cell type that may offer safety and targeting advantages, a proprietary manufacturing process that is not trivial to copy, and a set of collaborations with larger and more established partners. That said, the broader cell therapy market includes much larger, better‑funded rivals, and success will depend heavily on generating convincing clinical data before competitors capture the same space.

Innovation and R&D

Innovation and R&D Innovation is the core of Adicet’s story. Its platform centers on engineered gamma delta T‑cells designed to be manufactured in advance and given to many patients, instead of customizing cells for each individual. The company is pushing this platform in multiple directions: blood cancers, solid tumors, and even autoimmune diseases. Lead programs are already in human trials or approaching them, while earlier projects remain in preclinical testing. R&D efforts are clearly focused and increasingly concentrated on a smaller number of priority assets, which can be positive for execution but also raises concentration risk if those key programs disappoint. Overall, the company’s value is tightly linked to the success and safety profile of these experimental therapies.

Summary

Adicet Bio is a clinical‑stage biotech with a highly specialized cell therapy platform, no meaningful commercial revenue yet, and consistent operating losses. The balance sheet still shows positive equity and relatively low debt, but cash has been trending down, underscoring the importance of future fundraising or partnership support. The company’s main strengths lie in its differentiated gamma delta T‑cell approach, intellectual property, and ties to well‑known collaborators, along with a pipeline that stretches across oncology and autoimmune disease. On the risk side, Adicet faces the usual early‑stage biotech uncertainties: clinical and regulatory outcomes that are far from guaranteed, a need for ongoing external capital, and intense competition from larger players pursuing overlapping therapeutic areas. The long‑term outlook will hinge on upcoming clinical results, the ability to scale manufacturing, and management’s success in securing sufficient funding while advancing its key programs.

NEWS

November 28, 2025 · 2:23 PM UTC

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Read more

November 5, 2025 · 4:01 PM UTC

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Read more

October 31, 2025 · 4:59 PM UTC

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more

October 28, 2025 · 7:00 AM UTC

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Read more

October 16, 2025 · 7:00 AM UTC

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Read more